Safety and Efficacy of Intrauterine Biological Barrier on Postoperative Adhesion After Hysteroscopic Adhesiolysis

Last updated: July 23, 2022
Sponsor: Beijing Tiantan Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT05475756
RKM-GPSIS-CTP202201
  • Ages 20-40
  • Female

Study Summary

To evaluate the safety and efficacy of Intrauterine Biological Barrier developed and produced by Chengdu TopRegMed Medical Technology Co., Ltd on postoperative adhesion after Hysteroscopic Adhesiolysis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • （1）Age, yr20-40 (including boundary value), Female
  • （2）Normal ovarian reserve function (FSH<10U/ml，AMH>2ng/ml)
  • （3）Who suffered from moderate to severe intrauterine adhesions (AFS ≥ 5 points)diagnosed by hysteroscopy, and prepared to be treated by Hysteroscopic adhesiolysis
  • （4）Both husband and wife have fertility intention during treatment
  • （5）Accept to treatment and follow-up visits, Sign the ICF

Exclusion

Exclusion Criteria:

  • （1）Severe systemic diseases, contraindications of surgical and cycle
  • （2）Inflammation of reproductive tract, genital tuberculosis, pelvic infection, tumorof reproductive organs
  • （3）Systemic diseases cause uterine bleeding
  • （4）Allergic to hyaluronic acid or components
  • （5）Allergic to swine sources medical device, or refuse to swine sources medical devicefor religious, ethnic and other reasons
  • （6）Insufficient uterine cavity volume after Hysteroscopic adhesiolysis to placeIntrauterine Biological Barrier or inject Intrauterine Adhesion Barrier Gel
  • （7）Involved other clinical trial before Hysteroscopic adhesiolysis in 3 months orduring the trail
  • （8）Unable to tolerate anesthesia
  • （9）Estrogen medicine was taken within 30 days of Hysteroscopic adhesiolysis
  • （10）Other inadequacy patient assessed by the researchers

Study Design

Total Participants: 264
Study Start date:
February 25, 2022
Estimated Completion Date:
May 23, 2025

Study Description

This study is a prospective, multicenter, randomized, parallel positive-control, non-inferior clinical trial, with the purpose to evaluate the efficacy and safety of Intrauterine Biological Barrier for the prevention or reduction of intrauterine adhesions after Hysteroscopic Adhesiolysis.

The trial will be conducted at six clinical centers with 264 subjects who meet all the inclusion/ exclusion criteria. Subjects will be randomly assigned to the experimental group and the control group in a 1:1 ratio. Subjects in the test group were treated with Intrauterine Biological Barrier (IBB) made by Chengdu TopRegMed Medical Technology Co. , Ltd. , while the patients in the positive control group were treated with commercially approved Intrauterine Adhesion Barrier Gel for uterine cavity made by Changzhou Bioregen biopharmaceutical Co. , Ltd. .

Subjects will be followed up for 12 months (360 days ± 30 days) after implantation. 73-days (± 12 days) after operation, the safety and effectiveness of IBB will be evaluated by demonstrating non-inferiority to commercially approved gel. If test group is non-inferiority, further study will be performed to explore whether the safety and effectiveness of the IBB is better than the control group in the aspect of the recurrence rate of intrauterine adhesion, types of intrauterine adhesion, postoperative endometrial repair, menstrual recovery and 1-year pregnancy rate.

Connect with a study center

  • Anhui Provincial Hosptial

    Hefei, Anhui
    China

    Site Not Available

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing
    China

    Active - Recruiting

  • Zhangzhou Municipal Hospital of Fujian Province

    Zhangzhou, Fujian
    China

    Site Not Available

  • Guangzhou First people's Hospital

    Guangzhou, Guangdong
    China

    Site Not Available

  • Suzhou Municipal Hospital

    Suzhou, Jiangsu
    China

    Site Not Available

  • Tangdu Hospital

    Xi'an, Shanxi
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.